Association of First-Trimester Maternal Serum PAPP-A, Free β-hCG, and Placental Growth Factor with Adverse Pregnancy Outcomes: A Prospective Observational Study
IOSR Journal of Dental and Medical Sciences · 2026-06 · 25 (6) · 01-05
DOI: 10.9790/0853-2506030105 ↗Kurz gefasst
Fachartikel in der Zeitschrift IOSR Journal of Dental and Medical Sciences, 2026-06. Verfasst von Cheyne Rosetta Estibeiro und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Adverse pregnancy outcomes such as preeclampsia, fetal growth restriction, preterm delivery, and oligohydramnios contribute significantly to maternal and perinatal morbidity and mortality. Early identification of women at risk allows timely preventive interventions. Maternal serum biomarkers including pregnancyassociated plasma protein-A (PAPP-A), free beta-human chorionic gonadotropin (β-hCG), and placental growth factor (PlGF) have been proposed as early predictors of placental dysfunction and adverse pregnancy outcomes.
Objective
To evaluate the association of first-trimester maternal serum PAPP-A, free β-hCG, and PlGF levels with adverse pregnancy outcomes.
Methods
A prospective observational study was conducted among antenatal women between 9 weeks and 13 weeks + 6 days of gestation attending a tertiary care teaching hospital. Maternal serum PAPP-A, free β-hCG, and PlGF were measured during the first trimester using time-resolved fluoroimmunoassay. Participants were followed until delivery, and pregnancy outcomes were recorded. Statistical analysis was performed using Mann–Whitney U tests and multivariate logistic regression.
Results
A total of 123 women were enrolled, and 119 completed follow-up. Preeclampsia occurred in 6.72% of pregnancies, while preterm delivery and oligohydramnios occurred in 4.24% each. Gestational diabetes mellitus was observed in 2.52%, PROM in 3.36%, and fetal growth restriction in 3.40% of pregnancies. Multivariate analysis demonstrated significant associations between serum analytes and preeclampsia prediction (p=0.01). PlGF and PAPP-A showed the strongest relationship with preeclampsia risk. No significant associations were observed for most other adverse pregnancy outcomes.
Conclusion
First-trimester PlGF and PAPP-A are promising biomarkers for the prediction of preeclampsia. Incorporating PlGF into routine first-trimester screening may improve early identification of women at risk, allowing implementation of preventive measures such as low-dose aspirin therapy and enhanced antenatal surveillance.
Zitieren
APA
Estibeiro, C. R., & Khursheed, R. (2026). Association of First-Trimester Maternal Serum PAPP-A, Free β-hCG, and Placental Growth Factor with Adverse Pregnancy Outcomes: A Prospective Observational Study. IOSR Journal of Dental and Medical Sciences, 25(6), 01-05. https://doi.org/10.9790/0853-2506030105
Vancouver
Estibeiro CR, Khursheed R. Association of First-Trimester Maternal Serum PAPP-A, Free β-hCG, and Placental Growth Factor with Adverse Pregnancy Outcomes: A Prospective Observational Study. IOSR Journal of Dental and Medical Sciences. 2026;25(6):01-05. doi:10.9790/0853-2506030105
BibTeX
@article{Estibeiro2026,
author = {Estibeiro, Cheyne Rosetta and Khursheed, Rumana},
title = {Association of First-Trimester Maternal Serum PAPP-A, Free β-hCG, and Placental Growth Factor with Adverse Pregnancy Outcomes: A Prospective Observational Study},
journal = {IOSR Journal of Dental and Medical Sciences},
year = {2026},
volume = {25},
number = {6},
pages = {01--05},
doi = {10.9790/0853-2506030105}
}
EUVIMED